Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Payables (2019 - 2025)

C4 Therapeutics' Payables history spans 7 years, with the latest figure at $858000.0 for Q4 2025.

  • For Q4 2025, Payables fell 35.39% year-over-year to $858000.0; the TTM value through Dec 2025 reached $858000.0, down 35.39%, while the annual FY2025 figure was $858000.0, 35.39% down from the prior year.
  • Payables reached $858000.0 in Q4 2025 per CCCC's latest filing, down from $1.3 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $4.5 million in Q4 2021 to a low of $683000.0 in Q1 2025.
  • Average Payables over 5 years is $2.2 million, with a median of $1.6 million recorded in 2024.
  • Peak YoY movement for Payables: plummeted 73.99% in 2022, then skyrocketed 142.72% in 2025.
  • A 5-year view of Payables shows it stood at $4.5 million in 2021, then tumbled by 73.99% to $1.2 million in 2022, then rose by 23.38% to $1.4 million in 2023, then decreased by 8.16% to $1.3 million in 2024, then tumbled by 35.39% to $858000.0 in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Payables are $858000.0 (Q4 2025), $1.3 million (Q3 2025), and $2.2 million (Q2 2025).